Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab and Anlotinib with or without TACE in Advanced HCC
NCT05344924Phase 3Unknown
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of penpulimab, anlotinib in hepatocellular carcinoma (HCC), sponsored by Zhongda Hospital, Southeast University. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05344924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344924.